Financière de Tubize S.A.
TUB
Classement en actions
#2122
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Prix de l'action
$217.90
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$9.70B
Changement (1 jour)
5.57%
Changement (1 an)
-19.89%
Pays
BE
Échange Financière de Tubize S.A. (TUB)
Catégorie
Healthcare
EPS pour Financière de Tubize S.A. (TUB)
EPS au June 2026 TTM : $2.62
Selon les derniers rapports financiers et le cours de l'action de Financière de Tubize S.A., l’EPS actuel de la société (TTM) est de $2.62. À la fin de 2023, la société avait un EPS de $2.19 une augmentation par rapport à celui de 2022, qui était de $2.05.
Historique de l'EPS de Financière de Tubize S.A. de 2003 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $2.62 | 24.83% |
| 2024 | $2.10 | -3.97% |
| 2023 | $2.19 | 6.83% |
| 2022 | $2.05 | -4.16% |
| 2021 | $2.14 | -69.99% |
| 2020 | $7.12 | -25,913.77% |
| 2019 | $-0.03 | -100.37% |
| 2018 | $7.37 | -4.38% |
| 2017 | $7.70 | 79.89% |
| 2016 | $4.28 | -17.32% |
| 2015 | $5.18 | 214.76% |
| 2014 | $1.65 | -13.29% |
| 2013 | $1.90 | -17.32% |
| 2012 | $2.30 | 22.27% |
| 2011 | $1.88 | 198.71% |
| 2010 | $0.63 | -88.03% |
| 2009 | $5.25 | -18,644.17% |
| 2008 | $-0.03 | -102.18% |
| 2007 | $1.30 | -90.76% |
| 2006 | $14.08 | 80.81% |
| 2005 | $7.79 | 111.12% |
| 2004 | $3.69 | -20.63% |
| 2003 | $4.65 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | 560.72% |
US
|
|
| $-7.98 | -404.42% |
US
|
|
| $-5.29 | -301.80% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 958.21% |
NL
|
